Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trivalent influenza split vaccine (Shenzhen Kangtai)
- Development stage
- Preclinical
- Lead developer
- Shenzhen Kangtai Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Trivalent influenza split vaccine (Shenzhen Kangtai) is an inactivated split-virus vaccine developed by Shenzhen Kangtai Biological Products (also known as Kangtai Biotechnology) for the prevention of seasonal influenza. The vaccine is designed to induce protective immunity against three influenza virus strains, typically comprising two influenza A subtypes and one influenza B lineage. It contains purified surface antigens, primarily hemagglutinin and neuraminidase, from inactivated viruses. Indicated for individuals aged 3 years and older, the vaccine aims to stimulate the immune system to produce specific antibodies that neutralize the targeted influenza strains. As of the latest reports, the vaccine has reached the NDA/BLA filing stage in China.
- Other names
- 三价流感病毒裂解疫苗（3岁以上）Trivalent Influenza Split Vaccine (≥3 yrs)trivalent inactivated split-virus influenza vaccine
02
Targets
HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on trivalent influenza split vaccine (Shenzhen Kangtai).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trivalent influenza split vaccine (Shenzhen Kangtai).